Andrew Kay

Andrew Kay has extensive experience in the pharmaceutical and biotech industry. Andrew has held various positions, including Chairman of the Board at NuCana plc, WalkSafe Ltd., NERRE THERAPEUTICS LTD, Blueberry Therapeutics Ltd, and KaNDy Therapeutics. Andrew was also the Chairman of the Board at Wilson Therapeutics, which was acquired by Alexion Pharmaceuticals Inc. for $855 million. Additionally, they served as President and CEO at Algeta ASA, where they oversaw all activities in R&D, manufacturing, clinical trials, and regulatory affairs. Andrew was also a Main Board Director and Executive Commercial Director at Renovo, responsible for commercial activities, partnering and business development, and operations. Prior to these roles, they were the Head of Global Marketing and Sales at Novartis.

Andrew Kay attended Calday Grange Grammar School from 1967 to 1973. Andrew then went on to study at the University of Nottingham from 1973 to 1976, where they obtained a degree in Pharmacy with honors, specifically a B Pharm hons.